Recipient(s) will receive an email with a link to 'Advanced Maternal Age' and will have access to the topic for 7 days.
Subject: Advanced Maternal Age
(Optional message may have a maximum of 1000 characters.)
No universal definition for advanced maternal age because effects of aging exist as a continuum rather than threshold.
Generally accepted definition is at least 35 years of age or estimated delivery date older than age 35.
Advanced maternal age has a significant independent association with decreased fertility as well as increase in fetal and obstetric complications (1,2).
Rate of live birth for older women has been rising significantly over past three decades, as people are delaying childbearing due to cultural and sociologic changes.
From 1990 to 2008, birth rate per 1,000 women age 35–44 years increased from 18.7 to 28.7 (3).
Decline in fertility with age due to gradual decrease in quantity and quality of oocytes within the ovaries
As women age, there is a progressive loss of oocytes from fetal life through menopause (4).
Increased risk for aneuploidy and spontaneous abortion is due to changes in the meiotic spindle that predisposes to nondisjunction. However, no association has been found between nonaneuploid structural defects and maternal age (1,4).
Use of assisted reproductive techniques and ovulation induction has significantly contributed to increased rate of twin and triplet births, which further contributes to complications during pregnancy (1).
As women age, they have increased rates of chronic illness that affect fertility and contribute to obstetrical complications. A careful history should be obtained at initial visit that pays special attention to factors that can affect fertility and pregnancy such as
Sexually transmitted infections
Women with chronic conditions may be on medications that are contraindicated during pregnancy. A careful review of medications should be performed and alternatives considered when applicable.
Standard prenatal laboratory tests and imaging should be performed on women of advanced maternal age.
American College of Obstetricians and Gynecologists recommend all women who present before 20 weeks should be offered aneuploidy screening and option of diagnostic testing, regardless of maternal age (5)[B]. Decision to test for genetic anomalies is personal and based on many factors including family history of birth defects, risk of pregnancy loss, and impact of abnormal findings.
1st-trimester screening includes measurement of serum human chorionic gonadotropin (hCG or β-hCG) and pregnancy-associated plasma protein A (PAPP-A), usually combined with nuchal translucency measurement when available.
Large trials have demonstrated Down syndrome detection rates of 79–87% with false-positive rate of 5% (5).
Screening during 2nd trimester includes serum markers hCG, alpha fetoprotein (AFP), and unconjugated estriol.
When combined with a fourth marker, dimeric inhibin alpha, “quad” test has sensitivity for Down syndrome of up to 81% with 5% false-positive rate (5).
Some institutions may combine 1st- and 2nd-trimester markers into a single score (sequential testing). An integrated score may further increase sensitivity with lower false-positive rates (5)[B].
Noninvasive prenatal testing (NIPT) measuring cell-free fetal DNA circulating in maternal serum is a newer screening tool for fetal aneuploidy. It is indicated in singleton pregnancies for women at increased risk for aneuploidy, including maternal age older than 35 years at delivery (6).
NIPT may be used to screen for trisomy 21, trisomy 18, and, in some laboratories, trisomy 13 with detection rates of >98% with false-positive rates of less than 0.5% (6).
NIPT may be used as primary screening or as a follow-up screening test for women with positive 1st-trimester or 2nd-trimester test results (6).
Patients should be educated regarding the differences between screening and diagnostic tests for aneuploidy. Not all affected fetuses will be detected by screening. Some women may opt to have invasive testing (e.g., amniocentesis, chorionic villus sampling) without first undergoing screening. Pretest counseling should include a review of available screening and diagnostic modalities as well as discussion of the risks and benefits of each.
Aneuploidy is often associated with major birth anatomic malformations, which can often be detected via sonogram. Abnormal findings on 2nd-trimester ultrasound merits further counseling and offer of invasive testing (5)[B].
Use of serum markers for aneuploidy screening in multiple gestation is less accurate than in singleton pregnancies (5,6)[B].
Advanced maternal age has significant increased risks to both mother and fetus (1,2).
Women older than 35 years are at higher risk of
The fetus of a mother older than 35 years is at increased risk of
Perinatal mortality and neonatal death
Patients may minimize risks by treating preexisting conditions and should be counseled to optimize their well-being with healthy diet, exercise, and to avoid smoking.
Prenatal care for patients of advanced maternal age should follow same course and timeline as for younger women.
Closer monitoring or referral to maternal–fetal medicine may be warranted should complications arise.
Providers should discuss the potential consequences of delayed childbearing, including increased risk for infertility or developing chronic medical conditions, which might complicate pregnancy.
There is a misconception that advances in assisted reproductive technology can compensate for age-related decline in fertility. Women should be counseled that age is the single most important determinant of fertility, and assisted reproductive technology cannot reverse the effects of age (1).
V23.81 Supervision of high-risk pregnancy with elderly primigravida
V23.82 Supervision of high-risk pregnancy with elderly multigravida
659.50 Elderly primigravida, unspecified as to episode of care or not applicable
659.60 Elderly multigravida, unspecified as to episode of care or not applicable
O09.519 Supervision of elderly primigravida, unspecified trimester
O09.529 Supervision of elderly multigravida, unspecified trimester
O09.511 Supervision of elderly primigravida, first trimester
O09.521 Supervision of elderly multigravida, first trimester
O09.512 Supervision of elderly primigravida, second trimester
O09.513 Supervision of elderly primigravida, third trimester
O09.522 Supervision of elderly multigravida, second trimester
O09.523 Supervision of elderly multigravida, third trimester
416413003 advanced maternal age gravida (finding)
443460007 Multigravida of advanced maternal age (finding)
Advanced maternal age is independently associated with decreased fertility as well as increased obstetric and fetal complications.
Although majority of patients of advanced maternal age will have normal pregnancy and delivery, older women are more likely to have developed chronic medical conditions which can complicate prenatal and perinatal outcomes.
Risk of chromosomal abnormalities increases with maternal age, especially as women progress though their 30s. An individual older woman is more likely to have a true positive screen than a younger woman because prevalence of chromosomal abnormality is higher. Regardless of maternal age, all pregnant women should have the option of aneuploidy screening and diagnostic testing.
Patients should be counseled regarding possible consequences of delayed childbearing.